Table 1 Clinical findings and treatments of 27 colorectal T/NK cell lymphoma patients

No. of cases

9 (33%)

11 (41%)

7 (26%)

27

Median age (range), y

63 (47–84)

64 (50–74)

54 (43–69)

60 (43–84)

Male: female

6:3

7:4

6:1

19:8

Past history of UC

1 (11%)

0

1 (14%)

2 (7%)

Chronic diarrhea

5 (56%)

4 (36%)

2 (29%)

11 (41%)

Abdominal pain

4 (44%)

3 (27%)

4 (57%)

11 (41%)

Weight loss

4 (44%)

2 (18%)

0

6 (22%)

Fever

0

2 (18%)

2 (29%)

4 (15%)

Total protein (g/dl)

5.7 (4–6.6)

6.3 (5.4–7.2)

7.5 (5.9–8.4)

6.5 (4–8.4)

Albumin (g/dl)

3.1 (2.1–3.8)

3.4 (2.6–4)

3.9 (2.7–4.4)

3.5 (2.1–4.4)

LDH (U/l)

191 (112–288)^*

785 (262–2192)^*

184 (123–244)

387 (112–2192)

sIL-2R (U/ml)

1815 (587–4410)^*

51,643 (3501–154,246)^*

10,993 (1330–25,818)

21,484 (587–154,246)

Leukemic change

2 (22%)^**

6/8 (75%)^**

1 (14%)

9/21 (43%)

Clinical stage I

2 (22%)

0

2 (29%)

4 (15%)

 II (II1, II2, IIE)

3 (33%)

1 (9%)

2 (29%)

6 (22%)

  II1

1 (11%)

0

1 (14%)

2 (7%)

  II2

1 (11%)

0

0

1 (4%)

  IIE

1 (11%)

1 (9%)

1 (14%)

3 (11%)

IV

4 (44%)^**

10 (91%)^**

3 (42%)

17 (63%)

Surgery

1 (11%)

0

2 (29%)

3 (11%)

Surgery and chemotherapy

3 (33%)

1 (9%)

0

4 (15%)

Chemotherapy

2 (22%)^**

9 (82%)^**

3 (42%)

14 (52%)

Chemotherapy and SCT

2 (22%)

1 (9%)

0

3 (11%)

No treatment

1 (11%)

0

2 (29%)

3 (11%)